^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    LSD1 inhibitor

    Related drugs:
    Apply
    Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (NCT06514261)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    01/16/2025
    Initiation :
    12/18/2024
    Primary completion :
    09/16/2026
    Completion :
    09/16/2026
    TP53 • BCL2 • NF1 • MCL1 • BCL2L1 • BAX
    |
    Venclexta (venetoclax) • azacitidine • iadademstat (ORY-1001)
    Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT04734990)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/09/2024
    Initiation :
    07/07/2021
    Primary completion :
    09/11/2025
    Completion :
    09/11/2025
    TP53 • NRAS • RUNX1 • ASXL1 • SETBP1
    |
    TP53 mutation • NRAS mutation • ASXL1 mutation
    |
    azacitidine • seclidemstat (SP2577)
    Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA) (NCT05546580)
    Phase 1
    Oryzon Genomics S.A.
    Recruiting
    Last update posted :
    02/19/2024
    Initiation :
    11/14/2022
    Primary completion :
    01/31/2025
    Completion :
    07/30/2025
    FLT3
    |
    FLT3 mutation • FLT3 D835 • FLT3 I836
    |
    Xospata (gilteritinib) • iadademstat (ORY-1001)
    Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas (SALA-002-EW16) (NCT03600649)
    Phase 1
    Salarius Pharmaceuticals, LLC
    Active, not recruiting
    Last update posted :
    11/21/2023
    Initiation :
    06/04/2018
    Primary completion :
    09/01/2025
    Completion :
    12/01/2025
    EWSR1
    |
    cyclophosphamide • topotecan • seclidemstat (SP2577)
    Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI) (NCT04133948)
    Phase 1/2
    The Netherlands Cancer Institute
    Active, not recruiting
    Last update posted :
    11/15/2023
    Initiation :
    01/07/2020
    Primary completion :
    01/11/2022
    Completion :
    11/01/2024
    IFNG
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • domatinostat (4SC-202)
    A Study of CC-90011 and Comparators in Participants With Prostate Cancer (NCT04628988)
    Phase 1
    Celgene
    Completed
    Last update posted :
    09/13/2023
    Initiation :
    07/28/2021
    Primary completion :
    05/26/2023
    Completion :
    05/26/2023
    AR
    |
    AR expression
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • pulrodemstat (CC-90011)
    Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers (NCT04611139)
    Phase 1
    HonorHealth Research Institute
    Withdrawn
    Last update posted :
    03/01/2022
    Initiation :
    12/31/2021
    Primary completion :
    12/31/2023
    Completion :
    06/30/2024
    ARID1A
    |
    ARID1A mutation
    |
    Keytruda (pembrolizumab) • seclidemstat (SP2577)
    Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) (NCT03812796)
    Phase 2
    Royal Marsden NHS Foundation Trust
    Unknown status
    Last update posted :
    02/05/2019
    Initiation :
    01/11/2019
    Primary completion :
    11/30/2021
    Completion :
    11/30/2021
    MSI
    |
    Bavencio (avelumab) • domatinostat (4SC-202)